Is ZEVRA THERAPEUTICS, INC. (ZVRA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 11.9% / 30% | 13.7% / 30% | 2.1% / 30% | 9.21% / 5% | ✗ NOT HALAL |
| DJIM | 11.9% / 33% | 13.7% / 33% | 2.1% / 33% | 9.21% / 5% | ✗ NOT HALAL |
| MSCI | 33.9% / 33% | 39.0% / 33% | 5.9% / 33% | 9.21% / 5% | ✗ NOT HALAL |
| S&P | 11.9% / 33% | 13.7% / 33% | 2.1% / 33% | 9.21% / 5% | ✗ NOT HALAL |
| FTSE | 33.9% / 33% | 39.0% / 33% | 5.9% / 50% | 9.21% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 84.5% | |
| Operating Margin | 27.3% | |
| Net Margin | 78.2% | |
| Return on Equity (ROE) | 85.7% | |
| Return on Assets (ROA) | -1.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$2M |
| Free Cash Flow | -$2M |
| Total Debt | $63M |
| Debt-to-Equity | 40.9 |
| Current Ratio | 5.7 |
| Total Assets | $285M |
Price & Trading
| Last Close | $9.40 |
| 50-Day MA | $9.09 |
| 200-Day MA | $9.49 |
| Avg Volume | 1.1M |
| Beta | 0.9 |
|
52-Week Range
$6.19
| |
About ZEVRA THERAPEUTICS, INC. (ZVRA)
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is ZEVRA THERAPEUTICS, INC. (ZVRA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), ZEVRA THERAPEUTICS, INC. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is ZEVRA THERAPEUTICS, INC.'s debt ratio?
ZEVRA THERAPEUTICS, INC.'s debt ratio is 11.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 33.9%.
What are ZEVRA THERAPEUTICS, INC.'s key financial metrics?
ZEVRA THERAPEUTICS, INC. has a market capitalization of $538M, trailing P/E ratio of 6.8, and revenue of $106M. The company maintains a gross margin of 84.5% and a net margin of 78.2%. Return on equity stands at 85.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.